

Shigeru Iwata

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3389692/publications.pdf>

Version: 2024-02-01

62
papers

1,552
citations

331670

21
h-index

330143

37
g-index

65
all docs

65
docs citations

65
times ranked

1987
citing authors

#	ARTICLE	IF	CITATIONS
1	Neuropsychiatric systemic lupus erythematosus detected using extravascular spillage signal on dynamic magnetic resonance imaging (Ktrans). <i>Rheumatology</i> , 2022, 61, SI102-SI104.	1.9	1
2	An enhanced mitochondrial function through glutamine metabolism in plasmablast differentiation in systemic lupus erythematosus. <i>Rheumatology</i> , 2022, 61, 3049-3059.	1.9	19
3	Association of Viral Infection With the Development and Pathogenesis of Systemic Lupus Erythematosus. <i>Frontiers in Medicine</i> , 2022, 9, 849120.	2.6	14
4	Efficacy and safety of belimumab during maintenance therapy in patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2022, 61, 3614-3626.	1.9	10
5	Efficacy and safety of high-dose of mycophenolate mofetil compared with cyclophosphamide pulse therapy as induction therapy in Japanese patients with proliferative lupus nephritis. <i>Modern Rheumatology</i> , 2022, 32, 1077-1085.	1.8	1
6	Impact of serum interleukin-22 as a biomarker for the differential use of molecular targeted drugs in psoriatic arthritis: a retrospective study. <i>Arthritis Research and Therapy</i> , 2022, 24, 86.	3.5	5
7	Safety and efficacy of fostamatinib in rheumatoid arthritis patients with an inadequate response to methotrexate in phase II OSKIRA-ASIA-1 and OSKIRA-ASIA-1X study. <i>Rheumatology</i> , 2021, 60, 2884-2895.	1.9	14
8	Conversion of T Follicular Helper Cells to T Follicular Regulatory Cells by Interleukin-2 Through Transcriptional Regulation in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2021, 73, 132-142.	5.6	48
9	Pathological role of activated mTOR in CXCR3+ memory B cells of rheumatoid arthritis. <i>Rheumatology</i> , 2021, 60, 5452-5462.	1.9	7
10	Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis. <i>Arthritis Research and Therapy</i> , 2021, 23, 86.	3.5	22
11	A case of systemic lupus erythematosus with marked ascites due to idiopathic non-cirrhotic portal hypertension. <i>Modern Rheumatology Case Reports</i> , 2021, 5, 285-291.	0.7	4
12	Serum TNF \pm levels at 24 h after certolizumab pegol predict effectiveness at week 12 in patients with rheumatoid arthritis from Tsubame study. <i>Arthritis Research and Therapy</i> , 2021, 23, 154.	3.5	6
13	Therapeutic perspectives on the metabolism of lymphocytes in patients with rheumatoid arthritis and systemic lupus erythematosus. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 1121-1130.	3.0	3
14	mTOR activation in CD8+ cells contributes to disease activity of rheumatoid arthritis and increases therapeutic response to TNF inhibitors. <i>Rheumatology</i> , 2021, , .	1.9	4
15	T helper cells expressing fractalkine receptor and bearing T follicular helper 1-like cell functions in patients with IgG4-related disease. <i>Rheumatology</i> , 2021, , .	1.9	1
16	Involvement of lncRNA IL21-AS1 in interleukin-2 and T follicular regulatory cell activation in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2021, 23, 302.	3.5	12
17	Enhanced Fatty Acid Synthesis Leads to Subset Imbalance and IFN- γ Overproduction in T Helper 1 Cells. <i>Frontiers in Immunology</i> , 2020, 11, 593103.	4.8	12
18	Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation. <i>Arthritis Research and Therapy</i> , 2020, 22, 141.	3.5	10

#	ARTICLE	IF	CITATIONS
19	A case of bone destruction caused by chronic non-bacterial osteomyelitis (CNO) successfully repaired with a tumour necrosis factor- α (TNF- α) inhibitor, adalimumab. <i>Modern Rheumatology Case Reports</i> , 2020, 4, 196-201.	0.7	2
20	Tumour necrosis factor alpha promotes secretion of 14-3-3 β by inducing necroptosis in macrophages. <i>Arthritis Research and Therapy</i> , 2020, 22, 24.	3.5	16
21	The additive effects of hydroxychloroquine to maintenance therapy with standard of care in patients with systemic lupus erythematosus. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 549-558.	1.9	10
22	Two patients with mixed connective tissue disease complicated by pulmonary arterial hypertension showing contrasting responses to pulmonary vasodilators. <i>Modern Rheumatology Case Reports</i> , 2020, 4, 253-261.	0.7	1
23	An Autopsy Case with Cerebral Hemorrhaging due to disseminated Aspergillosis During Glucocorticoid Therapy for Overlap Syndrome of Systemic Lupus Erythematosus and Systemic Sclerosis. <i>Internal Medicine</i> , 2019, 58, 1023-1027.	0.7	4
24	Comparative study of corticosteroid monotherapy, and TNF inhibitors with or without corticosteroid in patients with refractory entero-Behçetâ€™s disease. <i>Arthritis Research and Therapy</i> , 2019, 21, 151.	3.5	13
25	A Study of the Vascular Endothelial Function in Patients with Type 2 Diabetes Mellitus and Rheumatoid Arthritis. <i>Internal Medicine</i> , 2019, 58, 1383-1390.	0.7	11
26	Lymphocyte phenotype and its application to precision medicine in systemic autoimmune diseasesâ€™. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 1146-1150.	3.4	18
27	THU0243â€™...ROLE OF METHIONINE AND ITS TRANSPORTER CD98 IN HUMAN B CELL DIFFERENTIATION AND THE RELEVANCE TO PATHOLOGICAL PROCESSES OF SLE. , 2019, , .		0
28	SAT0026â€™...IMPACT OF TOCILIZUMAB ON IMMUNE PHENOTYPES IN PATIENTS WITH LARGE VESSEL VASCULITIS. , 2019, , .		0
29	FRI0177â€™...THE ADDITIVE EFFECTS OF HYDROXYCHLOROQUINE TO MAINTENANCE THERAPY WITH STANDARD OF CARE IN PATIENTS WITH SYSTEMIC LUPUS: ERYTHEMATOSUS. , 2019, , .		0
30	THU0057Bâ€™...TNF-ALPHA INDUCES NECROPTOSIS-LIKE DEATH OF MACROPHAGES AND PROMOTES EXTRACELLULAR RELEASE OF 14â€™-3â€™-3ETA. , 2019, , .		0
31	Type I and II interferons commit to abnormal expression of chemokine receptor on B cells in patients with systemic lupus erythematosus. <i>Clinical Immunology</i> , 2019, 200, 1-9.	3.2	11
32	Effectiveness and safety of hydroxychloroquine therapy with or without corticosteroid in patients with systemic lupus erythematosus. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 434-442.	1.9	17
33	Evaluation of oxygen extraction fraction in systemic lupus erythematosus patients using quantitative susceptibility mapping. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019, 39, 1648-1658.	4.3	8
34	Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis. <i>Rheumatology</i> , 2019, 58, 336-344.	1.9	92
35	Intracranial vessel wall lesions in patients with systematic lupus erythematosus. <i>Journal of Magnetic Resonance Imaging</i> , 2018, 48, 1237-1246.	3.4	12
36	Differential effects of biological DMARDs on peripheral immune cell phenotypes in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2018, 57, 164-174.	1.9	70

#	ARTICLE	IF	CITATIONS
37	B cell phenotypes, signaling and their roles in secretion of antibodies in systemic lupus erythematosus. <i>Clinical Immunology</i> , 2018, 186, 21-25.	3.2	32
38	Th22 Cells Promote Osteoclast Differentiation via Production of IL-22 in Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2018, 9, 2901.	4.8	58
39	Relevance of interferon-gamma in pathogenesis of life-threatening rapidly progressive interstitial lung disease in patients with dermatomyositis. <i>Arthritis Research and Therapy</i> , 2018, 20, 240.	3.5	39
40	IgG4-related Pleuritis with Elevated Adenosine Deaminase in Pleural Effusion. <i>Internal Medicine</i> , 2018, 57, 2251-2257.	0.7	23
41	Hydroxychloroquine efficiently suppresses inflammatory responses of human class-switched memory B cells via Toll-like receptor 9 inhibition. <i>Clinical Immunology</i> , 2018, 195, 1-7.	3.2	66
42	Successful treatment with etanercept in a case of seronegative rheumatoid arthritis with corticosteroid/methotrexate-resistant pemphigus erythematosus. <i>Modern Rheumatology Case Reports</i> , 2018, 2, 137-142.	0.7	0
43	Metabolic Reprogramming Commits Differentiation of Human CD27+IgD+ B Cells to Plasmablasts or CD27 ^{hi} IgD ^{hi} Cells. <i>Journal of Immunology</i> , 2017, 199, 425-434.	0.8	72
44	Peripheral Immunophenotyping Identifies Three Subgroups Based on T Cell Heterogeneity in Lupus Patients. <i>Arthritis and Rheumatology</i> , 2017, 69, 2029-2037.	5.6	74
45	Enlarged perivascular spaces are associated with the disease activity in systemic lupus erythematosus. <i>Scientific Reports</i> , 2017, 7, 12566.	3.3	22
46	Abatacept therapy reduces CD28+CXCR5+ follicular helper-like T cells in patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 562-570.	0.8	16
47	Chemical JAK inhibitors for the treatment of rheumatoid arthritis. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2215-2225.	1.8	22
48	Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis. <i>BioDrugs</i> , 2016, 30, 407-419.	4.6	52
49	Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 1047-1057.	3.0	33
50	Amplification of IL-21 signalling pathway through Bruton's tyrosine kinase in human B cell activation. <i>Rheumatology</i> , 2015, 54, 1488-1497.	1.9	41
51	Tofacitinib, a JAK inhibitor, inhibits human B cell activation in vitro. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2213-2215.	0.9	38
52	The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2192-2198.	0.9	136
53	Abatacept inhibits radiographic progression in patients with rheumatoid arthritis: a retrospective analysis of 6 months of abatacept treatment in routine clinical practice. The ALTAIR study. <i>Modern Rheumatology</i> , 2013, , 1.	1.8	0
54	Structural damages disturb functional improvement in patients with rheumatoid arthritis treated with etanercept. <i>Modern Rheumatology</i> , 2012, 22, 186-194.	1.8	6

#	ARTICLE	IF	CITATIONS
55	Amplification of Toll-like receptor-mediated signaling through spleen tyrosine kinase in human B-cell activation. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 129, 1594-1601.e2.	2.9	43
56	Phenotypic Changes of Lymphocytes in Patients with Systemic Lupus Erythematosus Who Are in Longterm Remission After B Cell Depletion Therapy with Rituximab. <i>Journal of Rheumatology</i> , 2011, 38, 633-641.	2.0	60
57	Efficacy of combination therapy of anti-TNF- α antibody infliximab and methotrexate in refractory entero-Behçet's disease. <i>Modern Rheumatology</i> , 2011, 21, 184-191.	1.8	69
58	Efficacy of combination therapy of anti-TNF- α antibody infliximab and methotrexate in refractory entero-Behçet's disease. <i>Modern Rheumatology</i> , 2011, 21, 184-191.	1.8	50
59	Jak and Syk: Emerging their relevance to the treatment of inflammatory diseases. <i>Inflammation and Regeneration</i> , 2011, 31, 237-244.	3.7	6
60	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2). <i>Modern Rheumatology</i> , 2008, 18, 146-152.	1.8	61
61	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2). <i>Modern Rheumatology</i> , 2008, 18, 447-454.	1.8	40
62	A case of life-threatening refractory polychondritis successfully treated with combined intensive immunosuppressive therapy with methotrexate. <i>Modern Rheumatology</i> , 2007, 17, 144-147.	1.8	10